Table 5.
Effects of edaravone on oxidized low-density lipoprotein (OxLDL)
| Cortical group | Basal group | |
|---|---|---|
| Edaravone treatment group | – number of patients: 13 | – number of patients: 14 |
| – plasma OxLDL | – plasma OxLDL | |
| baseline: 0.219 ± 0.016 ng/µg of apoB protein on day 1 and 3, significantly lower than baseline day 3: 0.177 ± 0.024 ng/µg of apoB protein on day 1 and 3, significantly lower than that in non-edaravone group | baseline: 0.156 ± 0.013 ng/µg of apoB protein on day 7, significantly lower than that in the non-edaravone group | |
| – NIHSS score | – NIHSS score | |
| at hospitalization (average): 10.9 ± 2.5 | at hospitalization (average): 6.4 ± 2.3 | |
| → at discharge (average): 7.0 ± 1.2 (significant decrease, p<0.05) | → at discharge (average) : 3.6 ± 1.2 | |
| Non-edaravone treatment group | – number of patients: 11 | – number of patients: 13 |
| – plasma OxLDL | – plasma OxLDL | |
| baseline: 0.221 ± 0.028 ng/µg of apoB protein on days 1 and 3, higher than on day 0 | baseline: 0.157 ± 0.028 ng/µg of apoB protein | |
| day 3: 0.219 ± 0.026 ng/µg of apoB protein | ||
| – NIHSS score | – NIHSS score | |
| at hospitalization (average): 12.5 ± 2.8 | at hospitalization (average): 6.7 ± 3.7 | |
| → at discharge (average): 13.7 ± 4.2 | → at discharge (average): 6.8 ± 3.6 | |